CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Ocugen (OCGN) stock forecast: is there potential for growth?

By David Burrows

09:36, 20 August 2021

Ocugen stock forecast
Source: Shutterstock

There’s an old saying that it's “an ill-wind that blows nobody any good” and that certainly applies to Ocugen Inc (OCGN) stock.

In 2020, the biopharmaceutical firm Ocugen began developing a COVID-19 vaccine, Covaxin, in partnership with Bharat Biotech in India.

The decision by Ocugen, known for developing gene therapies for eye diseases, to turn its attention to engineering a COVID-19 vaccine – certainly had an impact. 

The share price rocketed, going from a low of just $0.17 in the middle of 2020 to $3.07 per share at the start 2021. The stock continued climbing and by early February it stood at $15.81 per share before dropping back to around $9 per share in March. It then rose sharply in late April to $12.67 before falling back again. It closed the day on 19 August at $7.16.

It is fair to say that those who timed the investment right in Ocugen will have done very well but given the volatility this stock has shown, is it now a stock you should buy or stay away from?

In general, the biotech sector has been a good hunting ground for investors – in late August 2020 the Nasdaq Biotech Index stood at 4198.64. By 19 August 2021 it had reached at 5152.82, representing a 21% gain over a one-year period.  Ocugen is just one of many in this space that have performed strongly – albeit with peaks and troughs along the way.

Ocugen stock analysis 

Ocugen stock news has not been hard to come by as the company has figured on the radar of many investors.

In June, the US decided against giving emergency use authorisation (EUA) to Covaxin, the vaccine developed with Bharat Biotech.

Last week, Bharat Biotech provided a final analysis for Covaxin efficacy from clinical trials. The analysis demonstrated Covaxin to be 77.8% effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group.

The analysis also showed Covaxin to be 93.4% effective against severe symptomatic COVID-19.

Under the terms of the partnership, Ocugen will take 45% of any profits that Covaxin generates in the US and Canada – assuming that the vaccine is made available there. But there are no guarantees of what these profits might be worth. Not only is there intense competition to provide vaccines in the US from the likes of ModernaPfizerBioNTech, and Johnson & Johnson but the vaccination programme in the US is well advanced.

This could be considered as a risk factor by investors, but let’s not forget that the company still has an interest in developing ground-breaking treatments for eye diseases. According to the company’s second quarter 2021 earnings report, released on 6 August 2021, Ocugen’s first candidate gene therapy for targeting retinal diseases, OCU400, will undergo phase 1/2a clinical trials in the US later this year and is evaluating options to start trials in Europe in 2022.

Ocugen’s financial performance doesn’t bode well for the OCGN stock price forecast, however, with the second quarter results missing analysts’ estimates. The figures indicated that Ocugen experienced a loss of 13 cents per share. This is less than the 19 cents per share loss incurred in the same quarter a year ago, but is much greater than Zacks’ predicted loss of just three cents per share.

As the company does not have any approved products at the moment, it hasn’t disclosed any revenues for the second quarter. Meanwhile, Ocugen’s R&D expenses comprised $18.9m compared to $1.6m for the same quarter a year ago. The company’s general and administrative expenses also increased by 278% from $1.8m for the second quarter of 2020 to $6.8m for the second quarter of this year.

Ocugen’s financial highlights Q2 2021

According to WallStreetZen, in 2023, OCGN is forecast to generate $290,183,513 in earnings, with the lowest earnings forecast at $166,954,898 and the highest earnings forecast at $365,710,729.


52,047.25 Price
-0.100% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00


0.56 Price
-1.500% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Oil - Crude

77.29 Price
+0.120% 1D Chg, %
Long position overnight fee 0.0081%
Short position overnight fee -0.0300%
Overnight fee time 22:00 (UTC)
Spread 0.030


17,493.40 Price
-0.160% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 22:00 (UTC)
Spread 1.8

On average, analysts forecast that OCGN's earnings per share (EPS) will be $-0.25 for 2021, with the lowest EPS forecast at $-0.33, and the highest EPS forecast at $-0.12. 

For 2022, analysts forecast that OCGN's EPS will be $0.25, with the lowest EPS forecast at $-0.25, and the highest EPS forecast at $0.65.

In 2023, OCGN's EPS is forecast to hit $1.46, with a maximum EPS of $1.84 and minimum EPS of $0.84.

Ocugen inc stock predictions and analyst ratings

According to the data by MarketBeat, five Wall Street analysts have chosen to  cover the OCGN stock price forecast for the next 12 months. At the time of writing, 19 August 2021, they share a consensus rating of hold, with three analysts indicating that the OCGN stock is a hold, and two give it a buy rating.

This could be considered a moderately bullish forecast for the Ocugen stock. The average price target is $7.66, which is just 7% higher than OCGN last closing price of $7.16.

Back in June 2021, Roth Capital said that it expects to see OCGN reach a price target of $6, having previously predicted a price of $10 and rated OCGN stocks as “neutral”. Later on, in July 2021, Robert LeBoyer from Noble Financial initiated his coverage of the Ocugen stock, rating it as a buy with a price target of $6.80. The latest analyst rating came out on 9 August 2021 from Swayampakula Ramakanth from HC Wainwright. He gave it a buy rating and an optimistic price target of $10.00

Ocugen: analyst ratings

These consensus estimates and recommendations are provided by analysts who track the evolution of the company’s fundamentals over time. They should not be taken as investment advice. These estimates are a reflection of their conclusions and views. They could be wrong. Investors should do their own research before investing in Ocugen stock or any other company.

Ocugen (OCGN) stock forecast 2021-2025

Algorithm-based stock analysis service Wallet Investor is currently bullish on Ocugen’s long-term share price trend.  Rating the company a buy, its Ocugen stock analysis provides an OCGN stock price forecast of $14.675 in one year and forecasts the stock will be worth $44.848 in five years.

Ocugen stock forecast 2021-2022

Stock research platform WallStreetZen, provides a slightly different picture.  Based on four analysts’ ratings for Ocugen, it grades OCGN stock as a hold. Only one of the four analysts, HC Wainwright & Co maintains a buy rating, setting a target price of $10.


What is happening with OCGN stock?

The Ocugen share price has seen plenty of volatility during 2021, as investors have responded to the biopharma company’s development of a COVID-19 vaccine and progress in its gene therapy for degenerative eye conditions.

Is Ocugen stock worth buying?

It all depends on your risk tolerance. Biopharma companies such as Ocugen are susceptible to dramatic share price moves based on the outcome of clinical trials for their products. The upside can be dramatic; as too can the downside. 

Will the Ocugen share price go up?

As we have seen from some of the research highlighted above, some analysts see the potential for the OCGN share price to return to double digits by the end of the year, others are less bullish and see the stock as a hold rather than a buy. 

This is certainly not a Steady Eddie stock - as can be seen by the volatile moves in the share price. Although the success in vaccine development could boost the company’s stock, it has no approved products yet and no revenue to show. If you are willing to take the risk, make sure you base your decisions on your own fundamental and technical analysis as analysts' predictions can be wrong. 

How to trade Ocugen shares with

Are you looking to take a position on the Ocugen share price? You can try to profit from the stock’s ongoing volatility by trading its shares with contracts for difference (CFDs) at CFDs are financial instruments that allow you to speculate on the direction of a stock price without having to commit to owning the underlying shares. 

If you expect the OCGN share price to rise you can open a long position, whereas if you think it will fall you can go short. As a leveraged product, CFDs are designed to maximise gains. However, you should be aware of the high risk involved as the use of leverage also magnifies losses if the asset price moves against you. 

Make sure you understand how CFDs work and do your own research before you start trading. Never invest money you cannot afford to lose. As always, you should be aware that past price performance is no guarantee of future returns.

Read more: What is a centralised exchange (CEX) and how does it work?

Markets in this article

BioNtech SE (Extended Hours)
91.44 USD
-0.53 -0.580%
BioNtech SE (Extended Hours)
91.44 USD
-0.53 -0.580%
Johnson & Johnson (Extended Hours)
157.90 USD
1.14 +0.730%
Johnson & Johnson (Extended Hours)
157.90 USD
1.14 +0.730%
Moderna Inc (Extended Hours)
86.97 USD
-1.98 -2.250%

Rate this article

The difference between trading assets and CFDs
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.
Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading